NASDAQ:ICCC ImmuCell Q3 2023 Earnings Report $5.50 +0.01 (+0.18%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$5.50 0.00 (-0.09%) As of 04/17/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Earnings History ImmuCell EPS ResultsActual EPS-$0.12Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AImmuCell Revenue ResultsActual Revenue$5.40 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AImmuCell Announcement DetailsQuarterQ3 2023Date11/13/2023TimeN/AConference Call DateTuesday, November 14, 2023Conference Call Time9:00AM ETUpcoming EarningsImmuCell's Q1 2025 earnings is scheduled for Wednesday, May 14, 2025, with a conference call scheduled on Thursday, May 15, 2025 at 9:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesConference Call AudioConference Call TranscriptSlide DeckPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfileSlide DeckFull Screen Slide DeckPowered by ImmuCell Q3 2023 Earnings Call TranscriptProvided by QuartrNovember 14, 2023 ShareLink copied to clipboard.There are 3 speakers on the call. Operator00:00:00Good day, everyone, and welcome to the ImmuCell Corporation's Third Quarter 2023 Financial Results Conference Call. All participants will be in listen only mode. After today's presentation, there will be an opportunity to ask questions. Please note this event is being recorded. And now, I would like to turn the conference over to Joe Diaz. Operator00:00:47Please go ahead. Speaker 100:00:50Thank you, Marlise. Good morning and welcome to everyone. As Marlise indicated, my name is Joe Diaz. I'm with Welcome partners. We are the Investor Relations consulting firm for ImmuCell. Speaker 100:01:02I thank all of you for joining us today to discuss the unaudited Financial results for the quarter ended September 30, 2023. I'd like to preface today's discussion with a caution Regarding forward looking statements, listeners are reminded that statements made by management during the course of this call include forward looking statements, which include any statement that refers to the future events or expected future results or predictions about steps the company plans to take in the future. These statements are not guarantees of performance and are subject to risks and uncertainties that could cause actual results, outcomes or events to differ materially from those discussed today. Additional information regarding forward looking statements and the risks and uncertainties that could impact future results, Outcomes or events is available under the cautionary note regarding forward looking statements or the Safe Harbor statement Provided on the quarterly report on Form 10 Q that the company filed last night, along with the company's other periodic filings with the SEC. Information discussed on today's call speaks only as of today, Tuesday, November 14, 2023. Speaker 100:02:18The company undertakes no obligation to update any information discussed on today's call. Please note that references to certain non GAAP financial measures may be made during today's call. The company included definitions of these terms as well as reconciliations of these figures to the most comparable GAAP financial measures in last night's press release in order to better assist you in understanding its financial performance. With that said, let me turn the call over to Michael Brigham, President and CEO of Immicell Corporation, after which we will open the call for your questions. Michael? Speaker 200:02:55Okay. Thanks, Joe, and good morning, everyone. First, with regards to the financial results, last night's press release reports No change to our product sales results that were first reported on October 5. The press release also provides We also filed our Form 10 Q for the quarter ended September 30, 2020 3 last night. I won't take our time here to review those financial results in great detail. Speaker 200:03:28Last night's press release also includes our non GAAP earnings before income taxes, depreciation and amortization or EBITDA. Please see Page 5 of the press release. You can see a significant swing of negative $3,600,000 from positive EBITDA of $1,300,000 during the 9 months ended September 30, 2022 to negative EBITDA of $2,300,000 during the 9 months ended $26,000 during the 9 months ended September 30, 'twenty two to $4,600,000 during the 9 months ended September 30, 23. The increase in the net loss was in turn largely caused by the $4,000,000 Decrease in gross margin earned from $6,700,000 during the 9 months ended September 30, 'twenty two to $2,600,000 during the 9 months ended September 30, 23. In response to this loss in cash, we took on more bank debt in July and have cut some discretionary spending and frozen several planned capital expenditure projects for the time being. Speaker 200:04:40All this is unfortunate, but necessary. We are focused intensely on working our way out of this tight situation by increasing production and sales. To be successful, we must avoid future significant So what is going on here? Let me try to speak to that. I'd like to point you to a disclosure being on Page 29 of our quarterly report or Page 31 of the agrized version that's filed with the SEC under the heading Production Capacity Increase, Production Contamination and Related Events, in which we review some of the significant challenges we have faced Over the last 12 months, that contributed to our current financial results. Speaker 200:05:23So after much work and some Significant delays by the end of 2022, we had completed all the facility improvements and the new equipment installations, including freeze dryer number 4 that are necessary to increase our estimated full production capacity to approximately $30,000,000 per year. Just as we began to operate at this higher level of capacity at the beginning of 2023, we were forced to slow down production to remediate a event related to our incoming raw material. At the very same time, freeze dryer number 2 stopped operating, requiring a 6 month repair, Denning us back to 3 operating freeze dryers. As of early July 23, we were back to operating for freeze dryers and we now believe these contamination events are largely, but not fully behind us. Finished goods produced increased steadily from approximately $3,300,000 to $4,000,000 and further to $5,300,000 during the first, second and third quarters of 2023, respectively. Speaker 200:06:27Our goal is to produce product with an estimated sales value of approximately $6,000,000 per quarter, which would annualize to about 80% of our estimated full production capacity of approximately 30,000,000 Our 3rd quarter production was approximately 89% of our quarterly objective. We have been driven by data as We resolved this temporary production problem. All production batches are routinely tested by our quality control team at the beginning, middle and end of the production process. Improvements throughout the production process from the depth of the contamination problem in January are allowing us to come back into full production. We believe that the operational improvements we have implemented will help us run more effectively at higher output level going forward. Speaker 200:07:16Despite this significant diversion of our resources, we made our 3rd submission of the CMC technical section for RETAIN to the FDA in August. This type of submission is subject to a 6 month review by the FDA. As disclosed on Page 35 of our quarterly report or Page 37 of the Edgar Rice version is filed with the SEC. The FDA notified us in late October That they have refused to review our August submission because of a misunderstanding about where and by whom we intend to have our drug product formulated and filled. The FDA thought our plan was to bring those services in house, which we might do down the road post approval rather than to continue with our contract manufacturer, which is still our current plan. Speaker 200:08:03In response to this notification from the FDA, we refiled our submission in November. We are on communication with the FDA To resolve this unfortunate miscommunication, but if we fail to reach agreement, the expected response date from their review could be delayed past February 2024, which is 6 months from the August submission date to as late as May 2024, which is 6 months The November resubmission date. Regardless, we remain poised and excited to revolutionize the way that subclinical mastitis is treated in today's dairy market With a novel alternative to traditional antibiotics with 0 milk discard and 0 meat withhold claims. As I said, The last 12 months have been very challenging for us for sure. We have worked incredibly hard to address these challenges and move forward. Speaker 200:08:56Based on our responses and progress, I'm optimistic about what we can do in the coming quarters. Lastly, I encourage you to review the press release and the quarterly Please also have a look at our corporate presentation slide deck. I believe it provides a very good summary of our business strategy and our objectives, as well as our current financial results. A November update was just posted to our website last night. You could see the Investors section Questions, let's have Marlise open up the lines. Operator00:09:35Thank you very much. And we'll begin the question and answer Since no questions are posed At this moment, I will then turn the conference back over to Joe Diaz for some closing remarks. Go ahead, Joe. Speaker 100:10:31Okay. Thank you, Marlise, and thanks all of you for participating in today's call. We look forward to talking with you again To review the results for the full year ended on December 31, 2023, sometime around late February 2020Read morePowered by Conference Call Audio Live Call not available Earnings Conference CallImmuCell Q3 202300:00 / 00:00Speed:1x1.25x1.5x2x Earnings DocumentsSlide DeckPress Release(8-K)Quarterly report(10-Q) ImmuCell Earnings HeadlinesTop Stock Reports for Netflix, SAP & ShellApril 17 at 11:50 AM | uk.finance.yahoo.comImmuCell appoints new CFO to bolster growth strategyApril 9, 2025 | uk.investing.comMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by using a secret we tested against every horrible thing that's happened to our financial system since 1991.April 20, 2025 | InvestorPlace (Ad)ImmuCell Corporation: ImmuCell Hires Chief Financial OfficerApril 9, 2025 | finanznachrichten.deImmucell reports preliminary Q1 revenue $8.1M vs. $7.3M last yearApril 9, 2025 | markets.businessinsider.comImmuCell Announces Preliminary, Unaudited Sales Results for Q1 of 2025April 8, 2025 | markets.businessinsider.comSee More ImmuCell Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like ImmuCell? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ImmuCell and other key companies, straight to your email. Email Address About ImmuCellImmuCell (NASDAQ:ICCC), an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.View ImmuCell ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Archer Aviation Unveils NYC Network Ahead of Key Earnings Report3 Reasons to Like the Look of Amazon Ahead of EarningsTesla Stock Eyes Breakout With Earnings on DeckJohnson & Johnson Earnings Were More Good Than Bad—Time to Buy? Why Analysts Boosted United Airlines Stock Ahead of EarningsLamb Weston Stock Rises, Earnings Provide Calm Amidst ChaosIntuitive Machines Gains After Earnings Beat, NASA Missions Ahead Upcoming Earnings Tesla (4/22/2025)Intuitive Surgical (4/22/2025)Verizon Communications (4/22/2025)Canadian National Railway (4/22/2025)Novartis (4/22/2025)RTX (4/22/2025)3M (4/22/2025)Capital One Financial (4/22/2025)General Electric (4/22/2025)Danaher (4/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
There are 3 speakers on the call. Operator00:00:00Good day, everyone, and welcome to the ImmuCell Corporation's Third Quarter 2023 Financial Results Conference Call. All participants will be in listen only mode. After today's presentation, there will be an opportunity to ask questions. Please note this event is being recorded. And now, I would like to turn the conference over to Joe Diaz. Operator00:00:47Please go ahead. Speaker 100:00:50Thank you, Marlise. Good morning and welcome to everyone. As Marlise indicated, my name is Joe Diaz. I'm with Welcome partners. We are the Investor Relations consulting firm for ImmuCell. Speaker 100:01:02I thank all of you for joining us today to discuss the unaudited Financial results for the quarter ended September 30, 2023. I'd like to preface today's discussion with a caution Regarding forward looking statements, listeners are reminded that statements made by management during the course of this call include forward looking statements, which include any statement that refers to the future events or expected future results or predictions about steps the company plans to take in the future. These statements are not guarantees of performance and are subject to risks and uncertainties that could cause actual results, outcomes or events to differ materially from those discussed today. Additional information regarding forward looking statements and the risks and uncertainties that could impact future results, Outcomes or events is available under the cautionary note regarding forward looking statements or the Safe Harbor statement Provided on the quarterly report on Form 10 Q that the company filed last night, along with the company's other periodic filings with the SEC. Information discussed on today's call speaks only as of today, Tuesday, November 14, 2023. Speaker 100:02:18The company undertakes no obligation to update any information discussed on today's call. Please note that references to certain non GAAP financial measures may be made during today's call. The company included definitions of these terms as well as reconciliations of these figures to the most comparable GAAP financial measures in last night's press release in order to better assist you in understanding its financial performance. With that said, let me turn the call over to Michael Brigham, President and CEO of Immicell Corporation, after which we will open the call for your questions. Michael? Speaker 200:02:55Okay. Thanks, Joe, and good morning, everyone. First, with regards to the financial results, last night's press release reports No change to our product sales results that were first reported on October 5. The press release also provides We also filed our Form 10 Q for the quarter ended September 30, 2020 3 last night. I won't take our time here to review those financial results in great detail. Speaker 200:03:28Last night's press release also includes our non GAAP earnings before income taxes, depreciation and amortization or EBITDA. Please see Page 5 of the press release. You can see a significant swing of negative $3,600,000 from positive EBITDA of $1,300,000 during the 9 months ended September 30, 2022 to negative EBITDA of $2,300,000 during the 9 months ended $26,000 during the 9 months ended September 30, 'twenty two to $4,600,000 during the 9 months ended September 30, 23. The increase in the net loss was in turn largely caused by the $4,000,000 Decrease in gross margin earned from $6,700,000 during the 9 months ended September 30, 'twenty two to $2,600,000 during the 9 months ended September 30, 23. In response to this loss in cash, we took on more bank debt in July and have cut some discretionary spending and frozen several planned capital expenditure projects for the time being. Speaker 200:04:40All this is unfortunate, but necessary. We are focused intensely on working our way out of this tight situation by increasing production and sales. To be successful, we must avoid future significant So what is going on here? Let me try to speak to that. I'd like to point you to a disclosure being on Page 29 of our quarterly report or Page 31 of the agrized version that's filed with the SEC under the heading Production Capacity Increase, Production Contamination and Related Events, in which we review some of the significant challenges we have faced Over the last 12 months, that contributed to our current financial results. Speaker 200:05:23So after much work and some Significant delays by the end of 2022, we had completed all the facility improvements and the new equipment installations, including freeze dryer number 4 that are necessary to increase our estimated full production capacity to approximately $30,000,000 per year. Just as we began to operate at this higher level of capacity at the beginning of 2023, we were forced to slow down production to remediate a event related to our incoming raw material. At the very same time, freeze dryer number 2 stopped operating, requiring a 6 month repair, Denning us back to 3 operating freeze dryers. As of early July 23, we were back to operating for freeze dryers and we now believe these contamination events are largely, but not fully behind us. Finished goods produced increased steadily from approximately $3,300,000 to $4,000,000 and further to $5,300,000 during the first, second and third quarters of 2023, respectively. Speaker 200:06:27Our goal is to produce product with an estimated sales value of approximately $6,000,000 per quarter, which would annualize to about 80% of our estimated full production capacity of approximately 30,000,000 Our 3rd quarter production was approximately 89% of our quarterly objective. We have been driven by data as We resolved this temporary production problem. All production batches are routinely tested by our quality control team at the beginning, middle and end of the production process. Improvements throughout the production process from the depth of the contamination problem in January are allowing us to come back into full production. We believe that the operational improvements we have implemented will help us run more effectively at higher output level going forward. Speaker 200:07:16Despite this significant diversion of our resources, we made our 3rd submission of the CMC technical section for RETAIN to the FDA in August. This type of submission is subject to a 6 month review by the FDA. As disclosed on Page 35 of our quarterly report or Page 37 of the Edgar Rice version is filed with the SEC. The FDA notified us in late October That they have refused to review our August submission because of a misunderstanding about where and by whom we intend to have our drug product formulated and filled. The FDA thought our plan was to bring those services in house, which we might do down the road post approval rather than to continue with our contract manufacturer, which is still our current plan. Speaker 200:08:03In response to this notification from the FDA, we refiled our submission in November. We are on communication with the FDA To resolve this unfortunate miscommunication, but if we fail to reach agreement, the expected response date from their review could be delayed past February 2024, which is 6 months from the August submission date to as late as May 2024, which is 6 months The November resubmission date. Regardless, we remain poised and excited to revolutionize the way that subclinical mastitis is treated in today's dairy market With a novel alternative to traditional antibiotics with 0 milk discard and 0 meat withhold claims. As I said, The last 12 months have been very challenging for us for sure. We have worked incredibly hard to address these challenges and move forward. Speaker 200:08:56Based on our responses and progress, I'm optimistic about what we can do in the coming quarters. Lastly, I encourage you to review the press release and the quarterly Please also have a look at our corporate presentation slide deck. I believe it provides a very good summary of our business strategy and our objectives, as well as our current financial results. A November update was just posted to our website last night. You could see the Investors section Questions, let's have Marlise open up the lines. Operator00:09:35Thank you very much. And we'll begin the question and answer Since no questions are posed At this moment, I will then turn the conference back over to Joe Diaz for some closing remarks. Go ahead, Joe. Speaker 100:10:31Okay. Thank you, Marlise, and thanks all of you for participating in today's call. We look forward to talking with you again To review the results for the full year ended on December 31, 2023, sometime around late February 2020Read morePowered by